Takara Bio Inc.
4974.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥45,039,000 | ¥43,505,000 | ¥78,142,000 | ¥67,699,000 |
| % Growth | 3.5% | -44.3% | 15.4% | – |
| Cost of Goods Sold | ¥18,972,000 | ¥16,597,000 | ¥33,377,000 | ¥18,488,000 |
| Gross Profit | ¥26,067,000 | ¥26,908,000 | ¥44,765,000 | ¥49,211,000 |
| % Margin | 57.9% | 61.9% | 57.3% | 72.7% |
| R&D Expenses | ¥6,897,000 | ¥8,324,000 | ¥8,575,000 | ¥6,109,000 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥16,907,000 | ¥15,581,000 | ¥15,649,000 | ¥14,200,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | -¥5,000 | -¥2,000 |
| Operating Expenses | ¥23,804,000 | ¥23,905,000 | ¥24,219,000 | ¥20,307,000 |
| Operating Income | ¥2,263,000 | ¥3,003,000 | ¥20,541,000 | ¥28,902,000 |
| % Margin | 5% | 6.9% | 26.3% | 42.7% |
| Other Income/Exp. Net | -¥266,000 | -¥150,000 | ¥683,000 | -¥1,370,000 |
| Pre-Tax Income | ¥1,997,000 | ¥2,853,000 | ¥21,224,000 | ¥27,532,000 |
| Tax Expense | ¥910,000 | ¥1,343,000 | ¥5,176,000 | ¥7,624,000 |
| Net Income | ¥1,042,000 | ¥1,480,000 | ¥16,012,000 | ¥19,849,000 |
| % Margin | 2.3% | 3.4% | 20.5% | 29.3% |
| EPS | 8.65 | 12.29 | 132.97 | 164.84 |
| % Growth | -29.6% | -90.8% | -19.3% | – |
| EPS Diluted | 8.65 | 12.29 | 132.97 | 164.84 |
| Weighted Avg Shares Out | 120,416 | 120,415 | 120,415 | 120,415 |
| Weighted Avg Shares Out Dil | 120,416 | 120,415 | 120,415 | 120,415 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥300,000 | ¥186,000 | ¥142,000 | ¥122,000 |
| Interest Expense | ¥20,000 | ¥23,000 | ¥24,000 | ¥23,000 |
| Depreciation & Amortization | ¥4,481,000 | ¥5,021,000 | ¥4,735,000 | ¥4,149,000 |
| EBITDA | ¥6,502,000 | ¥7,899,000 | ¥25,983,000 | ¥31,704,000 |
| % Margin | 14.4% | 18.2% | 33.3% | 46.8% |